Management of alopecia areata

BMJ (Online)

Volumn 341, Issue 7766, 2010, Pages 242-246

  Harries, M J ^a   Sun, J ^b,c   Paus, R ^a,d   King, L E ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b JACKSON LABORATORY   (United States)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^d UNIVERSITY OF LÜBECK   (Germany)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHENYLCYCLOPROPENONE; ALEFACEPT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; BEXAROTENE; CLOBETASOL PROPIONATE; CYCLOSPORIN A; DEXAMETHASONE; DIPHENCYPRONE; DITHRANOL; EFALIZUMAB; ESSENTIAL OIL; ETANERCEPT; FLUOCINOLONE ACETONIDE; LAVENDER OIL; METHOTREXATE; MINOXIDIL; PREDNISOLONE; PSORALEN; SALAZOSULFAPYRIDINE; SQUARIC ACID DIBUTYL ESTER; THYME OIL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ALOPECIA AREATA; AROMATHERAPY; ATROPHY; CLINICAL FEATURE; COCHRANE LIBRARY; DEPIGMENTATION; FOLLICULITIS; FUNGUS CULTURE; HAIR GROWTH; HUMAN; IMMUNOTHERAPY; MENTAL STRESS; OUTCOME ASSESSMENT; PAIN; PHYSICIAN; POPULATION; PRIORITY JOURNAL; PUVA; RELAPSE; REMISSION; REVIEW; SCALP; SINGLE DRUG DOSE; TINEA CAPITIS; TREATMENT RESPONSE; TRICHOTILLOMANIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ALOPECIA AREATA; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOTHERAPY; OFF-LABEL USE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955107561     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c3671     Document Type: Review

References (30)

1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ, 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70:628-33.
2. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database Syst Rev 2008;2:CD004413.
3. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol 2003;149:692-9.
4. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007;117:2019-27. (Pubitemid 47219540)
5. Walker SA, Rothman S. A statistical study and consideration of endocrine influences. J Invest Dermatol 1950;14:403-13.
6. Gip L, Lodin A, Molin L. Alopecia areata. A follow-up investigation of outpatient material. Acta Derm Venereol 1969;49:180-8.
7. Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 1971;85:272-3.
8. Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 1973;88:55-9.
9. Kubeyinje EP. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994;71:674-5.
10. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 2009;8:909-12.
11. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998;39:751-61. (Pubitemid 28519028)
12. Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001;137:1063-8. (Pubitemid 32756464)
13. Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000;136:1276-7.
14. Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20:1243-7. (Pubitemid 44614622)
15. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-tomoderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003;42:572-5.
16. Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003;49:96-8. (Pubitemid 36801639)
17. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970;141:193-202.
18. Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005;52:287-90.
19. Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol 1999;26:562-5. (Pubitemid 29462750)
20. Agarwal A, Nath J, Barua KN. Twice weekly 5 mg betamethasone oral pulse therapy in the treatment of alopecia areata. J Eur Acad Dermatol Venereol 2006;20:1375-6. (Pubitemid 44614670)
21. Luggen P, Hunziker T. High-dose intravenous corticosteroid pulse therapy in alopecia areata: own experience compared with the literature. J Dtsch Dermatol Ges 2008;6:375-8.
22. Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol 1979;115:1254-5. (Pubitemid 10153582)
23. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123:1491-3.
24. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL. Treatmentresistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990;126:756-9.
25. Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. BMJ 1983;287:1015-7.
26. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987;16:730-6.
27. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009;61:592 e1-9.
28. Hay IC, Jamieson M, Ormerod AD. Randomized trial of aromatherapy. Successful treatment for alopecia areata. Arch Dermatol 1998;134:1349-52.
29. Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG. Inosiplex for treatment of alopecia areata: a randomized placebo-controlled study. Acta Derm Venereol 2006;86:422-4.
30. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines - part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004;51:440-7.